RxDoctor Payments Data

Rao Gutta, MD

Vascular Surgery · Omaha, NENPI 1811936792

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (45.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 36.2% of the total. Reporting peaked in 2024 at $8,514 and has fallen 71.8% since, to $2,405 in 2025.

$20,714in general payments, 2019–2025

Across 280 payments — averaging $73.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$8K
  • W. L. Gore & Associates, Inc.$5K
  • Silk Road Medical, Inc.$2K
  • Siemens Medical Solutions USA, Inc.$1K
  • Inari Medical, Inc.$1K
  • Endologix LLC$503
  • plus $3K from 36 others
$6,047in research payments, 2019–2025

Across 6 payments — averaging $1007.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$6K

What the payments were for

  • Consulting fees$6,25030%
  • Travel & lodging$5,04024%
  • Food & beverage$9,42445%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,714 in reported general payments places this provider in the 85th percentile of 35 vascular surgery providers in Nebraska.

See all vascular surgery providers in Nebraska

Medicare billing

Part B allowed, 2024
$262,009
Medicare patients
1,197
Services billed
2,359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban14$14,831
EliquisApixaban14$10,228
ClopidogrelClopidogrel Bisulfate168$984
Gabapentin20$176
Atorvastatin Calcium15$19

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$178$14,83114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 vascular surgery providers in Nebraska.

Other vascular surgery in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →